AstraZeneca nabs priority review for Lynparza in prostate as PARP inhibitors expand to more cancers
Lynparza keeps rolling.
Three weeks after the FDA cleared the AstraZeneca drug as a first-line treatment of a particular form of advanced pancreatic cancer, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.